Lundbeck presents new real-world data highlighting meaningful improvements in patients severely impacted by migraine initiating Vyepti® , at HCOP Annual Conference

H. Lundbeck A/S Denmark

New six-month results from the Vyepti® (eptinezumab) 12-month, real-world INFUSE study presented at the 2026 Headache Cooperative of the Pacific (HCOP) Annual Conference, Ojai, California1The INFUSE study includes adults with migraine who had failed at least one preventive anti-calcitonin gene–related peptide (aCGRP) treatment1Clinically meaningful improvements reported across migraine frequency, responder rates and other patient-reported outcomes in adults switching to eptinezumab1and connect with us via LinkedIn.

References: 

Starling A et al. Poster Presentation: HCOP Annual Conference 2025Jaimes A et al. Headache 2025; 65:619–630.Iannone LF et al. Cephalalgia 2023;43:3331024231160519Overeem LH et al. Cephalalgia:3331024211048765Romozzi M et al. Headache, 2025;65:342–352Hong JB et al. J Headache Pain,2024; 25:90Straube A et al. J Headache Pain, 2023;24:59Steiner TJ, et al. J Headache Pain. 2018;19(1):17Leonardi M, et al. J Headache Pain. 2005; 6(6):429– 440Lipton RB, et al. J Neurol. 2023;270(12);5692–5710Ashina M, et al. Cephalalgia. 2020;40(3):241-254Lipton RB, et al. Neurology. 2020;94(13):e1365-e1377

CONTACT: 
H. Lundbeck A/S
Ottiliavej 9, 2500 Valby, Denmark
[phone]
[e-mail]

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/h--lundbeck-a-s/r/lundbeck-presents-new-real-world-data-highlighting-meaningful-improvements-in-patients-severely-impa,c4298837

The following files are available for download:

https://mb.cision.com/Main/18215/4298837/3902463.pdf

Press release HCOP Final

 

View original content:https://www.prnewswire.co.uk/news-releases/lundbeck-presents-new-real-world-data-highlighting-meaningful-improvements-in-patients-severely-impacted-by-migraine-initiating-vyepti-eptinezumab-at-hcop-annual-conference-302675109.html